HER2 Support Group Forums - View Single Post - "possible" prime cause of her2neu breast cancer PURPORTEDLY identified

01-23-2006, 05:39 PM

Or perhaps at least an early causative step. Amazing the claims put into the last sentence of abstracts! This is the Same post as Rhonda H earlier today--quite a claim! I put off posting it earlier waiting for the original article. Will post that once I get it! Definitely seems an overstretch!

ABSTRACT: Inefficient proteasomal-degradation pathway stabilizes AP-2? and activates HER-2/neu gene in breast cancer [International Journal of Cancer; Subscribe; Sample]
HER-2/neu proto-oncogene is overexpressed in about one fourth of human breast cancers. AP-2 transcription factors bind to the HER-2/neu gene promoter and activate its expression. In a striking concurrence, anomalous abundance of AP-2? protein or its homolog AP-2? is also detected with HER-2/neu protein in mammary tumor-derived cell lines. This suggests that the deregulation of AP-2 is the preceding pathogenic event and probably the pivotal one in this type of mammary carcinogenesis. We examined the process of AP-2? gene expression in mammary carcinoma cell lines to identify where the aberration had occurred. We found no amplification of the AP-2? gene. Its promoter was marginally upregulated; however, it did not significantly increase the mRNA levels. When the AP-2? protein was examined, a remarkable stability was seen in breast cancer cell lines MDA-MB-453 and SK-BR-3, with a half-life of over 30 hr. This is sharply higher than the approximate 1 hr observed in mammary epithelial cell line MCF-10A and murine cell line NIH 3T3. Treatment of MCF-10A and NIH 3T3 cells with the proteasome inhibitor MG-132 showed that AP-2? was ubiquitinated and its level significantly increased. Moreover, this increase was accompanied by elevated levels HER-2/neu protein. In contrast, weaker ubiquitination of AP-2? was seen in MDA-MB-453 and SK-BR-3 cancer cells, and MG-132 treatment did not raise the AP-2? level any further. These results uncover that unusual stability is the main mechanism that raises the levels of AP-2 proteins, and in addition, provide the first clue that defective ubiquitin-dependent proteasomal-degradation pathway is possibly the prime cause that affects the HER-2/neu gene and culminates in breast cancer.

01-23-2006, 05:39 PM	#1
Lani Guest Posts: n/a	"possible" prime cause of her2neu breast cancer PURPORTEDLY identified Or perhaps at least an early causative step. Amazing the claims put into the last sentence of abstracts! This is the Same post as Rhonda H earlier today--quite a claim! I put off posting it earlier waiting for the original article. Will post that once I get it! Definitely seems an overstretch! ABSTRACT: Inefficient proteasomal-degradation pathway stabilizes AP-2? and activates HER-2/neu gene in breast cancer [International Journal of Cancer; Subscribe; Sample] HER-2/neu proto-oncogene is overexpressed in about one fourth of human breast cancers. AP-2 transcription factors bind to the HER-2/neu gene promoter and activate its expression. In a striking concurrence, anomalous abundance of AP-2? protein or its homolog AP-2? is also detected with HER-2/neu protein in mammary tumor-derived cell lines. This suggests that the deregulation of AP-2 is the preceding pathogenic event and probably the pivotal one in this type of mammary carcinogenesis. We examined the process of AP-2? gene expression in mammary carcinoma cell lines to identify where the aberration had occurred. We found no amplification of the AP-2? gene. Its promoter was marginally upregulated; however, it did not significantly increase the mRNA levels. When the AP-2? protein was examined, a remarkable stability was seen in breast cancer cell lines MDA-MB-453 and SK-BR-3, with a half-life of over 30 hr. This is sharply higher than the approximate 1 hr observed in mammary epithelial cell line MCF-10A and murine cell line NIH 3T3. Treatment of MCF-10A and NIH 3T3 cells with the proteasome inhibitor MG-132 showed that AP-2? was ubiquitinated and its level significantly increased. Moreover, this increase was accompanied by elevated levels HER-2/neu protein. In contrast, weaker ubiquitination of AP-2? was seen in MDA-MB-453 and SK-BR-3 cancer cells, and MG-132 treatment did not raise the AP-2? level any further. These results uncover that unusual stability is the main mechanism that raises the levels of AP-2 proteins, and in addition, provide the first clue that defective ubiquitin-dependent proteasomal-degradation pathway is possibly the prime cause that affects the HER-2/neu gene and culminates in breast cancer.